**Claims**


1. Use of an IL-8 inhibitor in the manufacture of a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB).

2. The use of claim 1, wherein said IC/PBS and/or over active bladder (OAB) is induced by anticancer therapy or radiotherapy to the pelvis.

3. The use of claim 1 or claim 2, wherein said IL-8 inhibitor is a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor.

4. The use of any one of claims 1 to 3, wherein said IL8 inhibitor is selected from a small molecule, antibody or peptide.

5. The use of any one of claims 1 to 4, wherein said IL-8 inhibitor is a compound of formula (I)




(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;

X is OH;

R2 is hydrogen or linear $C_1$-$C_4$ alkyl;


Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched $C_1$-$C_4$ alkyl, linear or branched $C_1$-$C_4$ alkoxy, halo $C_1$-$C_3$ alkyl and halo $C_1$-$C_3$ alkoxy.

6. The use of any one of claims 1 to 5, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid

and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt.

7. The use of any one of claims 1 to 4, wherein said IL-8 inhibitor is a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula $SO_2Ra$ wherein Ra is linear or branched $C_1$-$C_4$ alkyl or halo $C_1$-$C_3$ alkyl.


8. The use of any one of claims 1 to 4 and 7, wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

9. A pharmaceutical composition for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB) comprising an IL-8 inhibitor wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;


X is OH;

R2 is hydrogen or linear $C_1$-$C_4$ alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched $C_1$-$C_4$ alkyl, linear or branched $C_1$-$C_4$ alkoxy, halo $C_1$-$C_3$ alkyl and halo $C_1$-$C_3$ alkoxy; or

d) a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula $SO_2Ra$ wherein Ra is linear or branched $C_1$-$C_4$ alkyl or halo $C_1$-$C_3$ alkyl.

10. The pharmaceutical composition as claimed in claim 9, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt, or wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

11. The pharmaceutical composition as claimed in claim 9 or claim 10, further comprising at least one further pharmaceutically active compound.


12. A product or kit comprising:

A) a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB) comprising an IL-8 inhibitor wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;


X is OH;

R2 is hydrogen or linear $C_1$-$C_4$ alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched $C_1$-$C_4$ alkyl, linear or branched $C_1$-$C_4$ alkoxy, halo $C_1$-$C_3$ alkyl and halo $C_1$-$C_3$ alkoxy; or

d) a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula $SO_2Ra$ wherein Ra is linear or branched $C_1$-$C_4$ alkyl or halo $C_1$-$C_3$ alkyl,

or the pharmaceutical composition according to claim 9 or claim 10, and

B) at least one further pharmaceutically active compound

A) and B) being two separate formulations for simultaneous, separate or sequential use.

13. The product or kit as claimed in claim 12, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt, or wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

14. The pharmaceutical composition as claimed in claim 11 or the kit as claimed in claim 12 or claim 13, wherein said further pharmaceutically active compound is an active compound useful for the prevention and treatment of IC/PBS, and/or OAB.

15. The pharmaceutical composition or the kit as claimed in claim 14, wherein said further pharmaceutically active compound is a TRPV1 antagonist.

16. The pharmaceutical composition as claimed in claim 11 or the kit as claimed in claim 12 or claim 13, wherein said further pharmaceutically active compound is a drug that induces, as an undesired effect, IC /PBS or OAB.

17. The pharmaceutical composition or the kit as claimed in claim 16, wherein said further pharmaceutically active compound is selected from cyclophosphamide, Bacillus Calmette-Guérin to be instilled directly into the bladder, mitomycin C, Adriamycin or tiaprofenic acid.